REVIEW Bentamapimod (AS602801) is a novel and orally active c-Jun-N-Terminal Kinase Inhibitor highly specific for JNK kinases. The inhibitorBentamapimod (AS602801) is a potent anti-inflammatory agent which has been shown to reduce the disease burden in several pre-clinical models for endometriosis, and has the potential to be effective in addressing the causes of post-operative abdominal adhesions. Pre-clinical data have demonstrated Bentamapimod to be an effective anti-inflammatory with anti-fibrotic properties. Bentamapimod (AS602801) showed good bioavailability in rats (F=50%) andBentamapimod (AS602801) does cross the blood brain barrier, with 98% brain penetration and so far the drug has been well tolerated. Bentamapimod (AS602801)is a potent and selective JNK inhibitor with therapeutic potential in MS and fibrosis as well.
All products are stocked and shipped from San Francisco Bay Area, California, USA.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.